FDA Brief

Warning letters Drugs

FDA warning letter to

Jamol Laboratories, Inc.

High riskIssued Jul 13, 2023Posted Aug 1, 2023Division of Pharmaceutical Quality Operations I

FDA found Jamol Laboratories making a nasal emollient under insanitary conditions and without adequate quality control, lab testing, or process validation.

What happened

FDA inspected Jamol Laboratories' drug manufacturing facility in Emerson, New Jersey, from December 5, 2022, to January 12, 2023. Investigators saw manufacturing in an uncontrolled multipurpose space in disrepair, including a dead insect, an exposed ceiling, inadequate ventilation, and a stained, debris-covered fan surrounded by cardboard in a corridor. The inspection also found CGMP (current good manufacturing practice) violations in the quality unit, laboratory testing, and process validation.

What FDA found

  1. The drug was prepared, packed, or held in an unclean, poorly maintained space that could contaminate it.

    Section 501(a)(2)(A) of the FD&C Act, 21 U.S.C. 351(a)(2)(A)
  2. The quality unit — the group responsible for oversight — had no written procedures for its roles, for investigating out-of-specification results and deviations, and did not make sure batch records were complete.

    21 CFR 211.22
  3. The test used to identify incoming eucalyptus oil was not specific enough; it did not include the infrared spectroscopy test the USP monograph requires.

    21 CFR 211.160(b)
  4. The firm did not test every batch of the drug for objectionable microorganisms, and did not assess botanical ingredients for aflatoxins or other mycotoxins.

    21 CFR 211.165(b)
  5. The firm never validated the manufacturing process and had no ongoing program to show that each lot comes out consistent and of the same quality.

    21 CFR 211.100(a)

What FDA wants

FDA tells the company to correct the violations promptly and reply in writing within 15 working days with what it has done, including a retrospective review of product on the U.S. market, testing of retained samples, and a process validation plan. If corrective actions cannot be finished in that time, the firm must state why and give a completion schedule.

Who should pay attention

  • brands and repackagers that buy OTC nasal or botanical drug products from contract manufacturers
  • companies whose products contain botanical ingredients and need aflatoxin and microbial testing
  • drugmakers whose quality units operate without written procedures or complete batch records

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. ABC Food Corp

    ABC Food Corp's ready-to-eat rice noodles and tofu were made without required hazard analysis and preventive controls.

    High risk
  3. Rama Food Manufacture Corp.

    FDA warns Rama Food Manufacture after inspections found insanitary conditions and preventive-control failures at its California ready-to-eat rice noodle plants.

    High risk
  4. Lewis Sausage Company Inc.

    FDA found Salmonella and Listeria in contract-made pet food from Lewis Sausage and says its pathogen controls are inadequate.

    High risk